Voyageur Pharmaceuticals Ltd. has achieved a significant milestone in pharmaceutical development with independent laboratory confirmation of pharmaceutical-grade purity for its natural barium sulfate active pharmaceutical ingredient sourced from the Frances Creek property in British Columbia. Testing conducted by SGS Laboratories in Mississauga, Ontario demonstrated barium sulfate assay results ranging from 98.1% to 99.4% across multiple samples, exceeding the United States Pharmacopeia monograph requirement of 97.5% with an average grade of 98.8%. All samples fully passed the complete suite of USP monograph tests, including identification, pH, loss on drying, limit of soluble barium salts, acid-soluble substances, sulfides, and microbiological requirements.
The material's processing characteristics proved equally promising, with pharmaceutical-grade micronizing equipment at Sturtevant Inc. producing excellent particle size distributions. Multiple test runs achieved d50 values of 1.1-1.9 µm and d90 values as low as 2.5 µm under optimal conditions, with all micronized samples meeting USP particle size and performance criteria while exhibiting good flowability, 100% yield, and no discoloration or contamination. The barium sulfate underwent a controlled acid-wash procedure developed and executed in a cGMP-compliant environment at SGS, with final processing and packaging completed under full Good Manufacturing Practices.
This development matters because it represents progress toward establishing a domestic North American supply chain for barium contrast media used in medical imaging procedures. Currently, the world's pharmaceutical barium sulfate is almost entirely synthetically produced, creating dependence on imported materials and potentially less effective imaging quality products. Voyageur's natural barite resource offers a potential alternative that could improve cost efficiency and supply reliability for hospitals and patients while providing higher quality imaging products.
With these results, Voyageur is set to advance to stage two of the Alberta Innovates AICE-Market Access Program, which will fund an upcoming clinical trial comparing the functional effectiveness of Voyageur's contrasts with current commercially available standard-of-care options for gastrointestinal Computed Tomography and fluoroscopic imaging applications. The clinical trial, designed by Chief Scientific Officer Dr. Iryna Saranchova in accordance with Health Canada standards and internationally recognized regulatory requirements, will evaluate investigational agents against both barium-based and iodinated oral contrasts to provide comprehensive assessment of product performance in clinical settings.
Successful study outcomes could validate clinical performance of Voyageur's developing imaging contrasts, strengthen regulatory positioning, and accelerate progress toward market adoption. The clinical trial results will be pivotal for marketing and enhancing the Company's FDA licensing applications, with the FDA process beginning in the first quarter of 2026. Full study completion is targeted for the fourth quarter of 2026, with results also contributing to the prefeasibility and final feasibility study for the Frances Creek project expected by the same timeframe.
Brent Willis, CEO of Voyageur, stated that these results represent a major de-risking milestone that brings the company significantly closer to a fully integrated, secure, and cost-effective North American supply chain for barium contrast media. The company has developed five barium contrast products that have Health Canada licenses and aims to become the first vertically integrated company in the radiology contrast media drug market by controlling all primary input costs from raw material sourcing to final production.
In separate corporate developments, Voyageur announced it has issued 378,651 Deferred Share Units to directors and a consultant pursuant to its fixed 10% equity incentive compensation plan, with each DSU having a starting value equal to approximately $0.17573 based on weighted average share prices for quarters ended September 30, 2025 and December 31, 2025. The company also granted 4,300,000 stock options to directors and officers exercisable at $0.1125 per share for ten years, plus options for 500,000 common shares at $0.18 per share to a contractor. Additionally, subject to TSX Venture Exchange approval, Voyageur intends to issue units comprised of common shares and warrants to an arm's length third party at a total deemed value of $100,000 in connection with debt incurred for financial advisory services.
